XBiotech lines up for a $76M IPO to fund its antibody R&D

Austin, TX's XBiotech has filed to make a $76 million Wall Street debut, plotting to bankroll a fleet of antibody therapies and an ambitious plan for a manufacturing and R&D campus. The company expects to offer 4 million shares at between $18 and $20 each, earmarking the majority of its proceeds to pay for Phase III trials on Xilonix, an interleukin-1 blocker with applications in multiple cancers. XBiotech plans to set aside $12 million of its haul to fund construction on a 46,000-square-foot operation in Austin, to which it is adding a commercial manufacturing facility. More

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.